当前位置: 首页 >> 检索结果
901. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
作者: Angel Lanas.;John A Baron.;Robert S Sandler.;Kevin Horgan.;Jim Bolognese.;Bettina Oxenius.;Hui Quan.;Douglas Watson.;Tomas J Cook.;Robert Schoen.;Carol Burke.;Susan Loftus.;Yaron Niv.;Robert Ridell.;Dion Morton.;Robert Bresalier.
来源: Gastroenterology. 2007年132卷2期490-7页
Our aim was to establish the incidence of symptomatic upper gastrointestinal ulcers, ulcer perforation, ulcer obstruction, or bleeding episodes (PUBs) associated with the use of selective cyclooxygenase-2 inhibitors at standard clinical doses compared with placebo. We report here on the PUB outcomes associated with the use of rofecoxib 25 mg in a 3-year, multicenter, double-blind, placebo-controlled trial designed to determine the effect of rofecoxib on the risk of recurrent neoplastic polyps of the colon.
902. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention.
作者: Jan Carstens.;Henning Grønbaek.;Helle K Larsen.;Erling B Pedersen.;Hendrik Vilstrup.
来源: BMC Gastroenterol. 2007年7卷1页
Sodium retention and ascites are serious clinical problems in cirrhosis. Urodilatin (URO) is a peptide with paracrine effects in decreasing sodium reabsorption in the distal nephron. Our aim was to investigate the renal potency of synthetic URO on urine sodium excretion in cirrhosis patients with sodium retention and ascites.
903. Actions by angiotensin II on esophageal contractility in humans.
作者: Anna Casselbrant.;Anders Edebo.;Johanna Wennerblom.;Hans Lönroth.;Herbert F Helander.;Michael Vieth.;Lars Lundell.;Lars Fändriks.
来源: Gastroenterology. 2007年132卷1期249-60页
Angiotensin II is a potent activator of smooth muscles but has not been much investigated with regard to gastrointestinal motor activity. This study explores expression of the renin-angiotensin system (RAS) in human esophageal musculature and actions by Angiotensin II both in vitro and in vivo.
904. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
作者: Mitchell L Shiffman.;Marc G Ghany.;Timothy R Morgan.;Elizabeth C Wright.;Gregory T Everson.;Karen L Lindsay.;Anna S F Lok.;Herbert L Bonkovsky.;Adrian M Di Bisceglie.;William M Lee.;Jules L Dienstag.;David R Gretch.
来源: Gastroenterology. 2007年132卷1期103-12页
Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment.
905. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
作者: Stefan Schreiber.;Ali Keshavarzian.;Kim L Isaacs.;John Schollenberger.;Juan P Guzman.;Cesare Orlandi.;Stephen B Hanauer.
来源: Gastroenterology. 2007年132卷1期76-86页
Tetomilast (OPC-6535), a novel thiazole compound, inhibits phosphodiesterase-4 and proinflammatory functions of leukocytes including superoxide production and cytokine release.
906. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
作者: Michael A Kamm.;William J Sandborn.;Miguel Gassull.;Stefan Schreiber.;Lechoslaw Jackowski.;Todd Butler.;Andrew Lyne.;David Stephenson.;Mary Palmen.;Raymond E Joseph.
来源: Gastroenterology. 2007年132卷1期66-75; quiz 432-3页
SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver the active drug throughout the colon. We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcerative colitis. A delayed-release oral mesalamine (ASACOL; Procter & Gamble, Cincinnati, OH) reference arm was included.
907. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
作者: Jean-Frédéric Colombel.;William J Sandborn.;Paul Rutgeerts.;Robert Enns.;Stephen B Hanauer.;Remo Panaccione.;Stefan Schreiber.;Dan Byczkowski.;Ju Li.;Jeffrey D Kent.;Paul F Pollack.
来源: Gastroenterology. 2007年132卷1期52-65页
This study evaluated the efficacy and safety of adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody administered subcutaneously, in the maintenance of response and remission in patients with moderate to severe Crohn's disease (CD).
908. The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.
作者: Nimer Assy.;Mohib Kayal.;Yoram Mejirisky.;Miguel Gorenberg.;Osamah Hussein.;Sorina Schlesinger.
来源: BMC Gastroenterol. 2006年6卷39页
Patients with compensated Child-A cirrhosis have sub clinical hypovolemia and diuretic treatment could result in renal impairment.
909. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
作者: Herbert L Bonkovsky.;Deepa Naishadham.;Richard W Lambrecht.;Raymond T Chung.;John C Hoefs.;S Russell Nash.;Thomas E Rogers.;Barbara F Banner.;Richard K Sterling.;John A Donovan.;Robert J Fontana.;Adrian M Di Bisceglie.;Marc G Ghany.;Chihiro Morishima.; .
来源: Gastroenterology. 2006年131卷5期1440-51页
Iron overload may cause or contribute to hepatic injury and fibrosis. Mutations in the HFE gene may influence development or progression of chronic liver disease by increasing iron stores or modulating immune responses. The aim of this work was to assess the influence of HFE mutations and serum and hepatic measures of iron status on baseline features and response to lead-in therapy in subjects with advanced chronic hepatitis C enrolled in the Hepatitis C Anti-viral Long-term Treatment to prevent Cirrhosis (HALT-C) Trial.
910. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions.
作者: Filippo Cremonini.;Michael Camilleri.;Maria Vazquez Roque.;Sanna McKinzie.;Duane Burton.;Kari Baxter.;Alan R Zinsmeister.
来源: Gastroenterology. 2006年131卷5期1431-9页
Ghrelin is secreted by the stomach and stimulates food intake. Obese individuals have lower fasting plasma ghrelin levels but increased appetite, suggesting greater responses to endogenous ghrelin in obesity. The aim of this study was to compare effects of exogenous ghrelin (at a dose that stimulates growth hormone [GH] release in the physiologic range) versus placebo on gastric emptying, gastric volume, and postprandial symptoms and determine whether body mass (ranging from normal weight to obesity) influences responses to ghrelin.
911. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.
作者: Michael R Konikoff.;Richard J Noel.;Carine Blanchard.;Cassie Kirby.;Sean C Jameson.;Bridget K Buckmeier.;Rachel Akers.;Mitchell B Cohen.;Margaret H Collins.;Amal H Assa'ad.;Seema S Aceves.;Philip E Putnam.;Marc E Rothenberg.
来源: Gastroenterology. 2006年131卷5期1381-91页
Eosinophilic esophagitis is an increasingly recognized disorder with distinctive endoscopic, histologic, and allergic features. Although several therapies are advocated, no placebo-controlled trials have been conducted. We aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinophilic esophagitis.
912. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
作者: Stephanos J Hadziyannis.;Nicolaos C Tassopoulos.;E Jenny Heathcote.;Ting-Tsung Chang.;George Kitis.;Mario Rizzetto.;Patrick Marcellin.;Seng Gee Lim.;Zachary Goodman.;Jia Ma.;Carol L Brosgart.;Katyna Borroto-Esoda.;Sarah Arterburn.;Steven L Chuck.; .
来源: Gastroenterology. 2006年131卷6期1743-51页
Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued. We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for up to 240 weeks.
913. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
作者: John A Baron.;Robert S Sandler.;Robert S Bresalier.;Hui Quan.;Robert Riddell.;Angel Lanas.;James A Bolognese.;Bettina Oxenius.;Kevin Horgan.;Susan Loftus.;Dion G Morton.; .
来源: Gastroenterology. 2006年131卷6期1674-82页
In human and animal studies, nonsteroidal anti-inflammatory drugs have been associated with a reduced risk of colorectal neoplasia. Although the underlying mechanisms are unknown, inhibition of cyclooxygenase (COX), particularly COX-2, is thought to play a role. We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas.
914. Computed tomographic colonography: assessment of radiologist performance with and without computer-aided detection.
作者: Steve Halligan.;Douglas G Altman.;Susan Mallett.;Stuart A Taylor.;David Burling.;Mary Roddie.;Lesley Honeyfield.;Justine McQuillan.;Hamdan Amin.;Jamshid Dehmeshki.
来源: Gastroenterology. 2006年131卷6期1690-9页
In isolation, computer-aided detection (CAD) for computed tomographic (CT) colonography is as effective as optical colonoscopy for detection of significant adenomas. However, the unavoidable interaction between CAD and the reader has not been addressed.
915. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.
作者: Laura E Moreno Luna.;Benjamin Kipp.;Kevin C Halling.;Thomas J Sebo.;Walter K Kremers.;Lewis R Roberts.;Emily G Barr Fritcher.;Michael J Levy.;Gregory J Gores.
来源: Gastroenterology. 2006年131卷4期1064-72页
Two advanced cytologic techniques for detecting aneuploidy-digital image analysis (DIA) and fluorescence in situ hybridization (FISH)-have recently been developed to help identify malignant pancreatobiliary strictures. The aim of this study was to assess the clinical utility of cytology, DIA, and FISH for the identification of malignant pancreatobiliary strictures.
916. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
作者: Javier Fernández.;Luis Ruiz del Arbol.;Cristina Gómez.;Rosa Durandez.;Regina Serradilla.;Carlos Guarner.;Ramón Planas.;Vicente Arroyo.;Miguel Navasa.
来源: Gastroenterology. 2006年131卷4期1049-56; quiz 1285页
Oral norfloxacin is the standard of therapy in the prophylaxis of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage. However, during the last years, the epidemiology of bacterial infections in cirrhosis has changed, with a higher incidence of infections caused by quinolone-resistant bacteria. This randomized controlled trial was aimed to compare oral norfloxacin vs intravenous ceftriaxone in the prophylaxis of bacterial infection in cirrhotic patients with gastrointestinal bleeding.
917. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
作者: Jean-Pierre Bronowicki.;Denis Ouzan.;Tarik Asselah.;Hervé Desmorat.;Jean-Pierre Zarski.;Juliette Foucher.;Marc Bourlière.;Christophe Renou.;Albert Tran.;Pascal Melin.;Christophe Hézode.;Michelle Chevalier.;Magali Bouvier-Alias.;Stéphane Chevaliez.;François Montestruc.;Isabelle Lonjon-Domanec.;Jean-Michel Pawlotsky.
来源: Gastroenterology. 2006年131卷4期1040-8页
Pegylated interferon alfa-ribavirin combination is the standard treatment for chronic hepatitis C, but the mechanisms by which ribavirin enhances the rate of sustained hepatitis C virus (HCV) eradication remain unknown. We aimed to investigate the role of ribavirin in HCV clearance during therapy and to evaluate the consequences of ribavirin discontinuation in patients infected with genotype 1 hepatitis C who cleared HCV RNA at week 24.
918. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
作者: Hendrik W Reesink.;Stefan Zeuzem.;Christine J Weegink.;Nicole Forestier.;Andre van Vliet.;Jeroen van de Wetering de Rooij.;Lindsay McNair.;Susan Purdy.;Robert Kauffman.;John Alam.;Peter L M Jansen.
来源: Gastroenterology. 2006年131卷4期997-1002页
VX-950 specifically inhibits the NS3.4A protease of hepatitis C and has antiviral activity in vitro. This phase I, placebo-controlled, double-blind study evaluated the antiviral activity, pharmacokinetics, and safety of VX-950 in patients with chronic hepatitis C (CHC).
919. A randomized, controlled trial of transanal irrigation versus conservative bowel management in spinal cord-injured patients.
作者: Peter Christensen.;Gabriele Bazzocchi.;Maureen Coggrave.;Rainer Abel.;Claes Hultling.;Klaus Krogh.;Shwan Media.;Søren Laurberg.
来源: Gastroenterology. 2006年131卷3期738-47页
Bowel dysfunction in patients with spinal cord injury often causes constipation, fecal incontinence, or a combination of both with a significant impact on quality of life. Transanal irrigation improves bowel function in selected patients. However, controlled trials of different bowel management regimens are lacking. The aim of the present study was to compare transanal irrigation with conservative bowel management (best supportive bowel care without irrigation).
920. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial.
作者: Richard Rothstein.;Charles Filipi.;Karel Caca.;Ronald Pruitt.;Klaus Mergener.;Alfonso Torquati.;Gregory Haber.;Yang Chen.;Kenneth Chang.;David Wong.;Jacques Deviere.;Douglas Pleskow.;Charles Lightdale.;Alain Ades.;Richard Kozarek.;William Richards.;Anthony Lembo.
来源: Gastroenterology. 2006年131卷3期704-12页
The aim of this study was to determine the effectiveness of endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease (GERD) in comparison with a sham procedure.
|